Inferra AI / Company / TEM
Tempus Ai, Inc.
TEM · Information Technology
Last earnings Jul 30, 2026
Key results
Revenuequarter
89.6%
Revenue increased 89.6% year-over-year to $314.6 million in the second quarter
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
Genomics revenuequarter
115.3%
Genomics revenue increased 115.3% year-over-year to $241.8 million on accelerating year-over-year volume growth in Oncology (26%) and Hereditary (32%) testing Data and services
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
revenue increased 35.7% year-over-year to $72.8 million, led by Insights (data licensing), which grew 40.7% year-over-year Quarterly gross profit was $195.0 million
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
Quarterly revenuequarter
89.6%
” Second Quarter Summary Results Quarterly revenue increased 89.6% year-over-year to $314.6 million.
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
Genomics contributed $241.8 million in revenue in the quarter, growing 115.3% compared to the second quarter of 2024.
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
Growthquarter
up 32.9%
Oncology testing (Tempus genomics) delivered $133.2 million of revenue, up 32.9% year-over-year with approximately 26% volume growth versus 20% last quarter.
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
Hereditary testing (Ambry genetics) contributed $97.3 million of revenue, up 33.6% year-over-year on a pro forma basis 1 with approximately 32% volume growth.
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
Revenue from Data and services totaled $72.8 million in the second quarter, delivering 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), which grew 40.7% year-over-year.
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
AI analysis
Q2 2025 · reported Aug 8, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | 89.6% | — | — |
| Genomics revenue | 115.3% | — | — |
| Quarterly revenue | 89.6% | — | — |
| Growth | up 32.9% | — | — |
Guidance · company-stated
Direction: raised
No guidance located in the held release
“22 ) (82 )% Financial Outlook and Guidance Tempus is increasing its full year 2026 revenue guidance to $1.”
Capital allocation
Second Quarter and Recent Operational Highlights Strengthened Financial Flexibility: Just after quarter end, we completed an upsized offering of $750 million 0.75% convertible senior notes, enhancing our balance sheet and allowing us to replace a portion of the existing term loan with a significantly lower interest debt instrument.
Recently Adopted Accounting Standards In November 2024, the FASB issued ASU 2024-04, Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments , which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions.
Event summary
Tempus Reports Second Quarter 2025 Results
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Second Quarter and Recent Operational Highlights Strengthened Financial Flexibility: Just after quarter end, we completed an upsized offering of $750 million 0.75% convertible senior notes, enhancing our balance sheet and allowing us to replace a portion of the existing term loan with a significantly lower interest debt instrument.
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
Recently Adopted Accounting Standards In November 2024, the FASB issued ASU 2024-04, Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments , which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions.
SEC original ↗Tempus Ai, Inc. — 10-Q Quarterly report10-QJul 30, 2026
Strategy & priorities
In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting.
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
, together with the subsidiaries through which it conducts business (the Company ), is a healthcare technology company focused on bringing artificial intelligence and machine learning to healthcare in order to improve the care of patients across multiple diseases.
SEC original ↗Tempus Ai, Inc. — 10-Q Quarterly report10-QJul 30, 2026
In addition, the Ambry Acquisition complements the Company's strategy of using data to advance clinical and scientific innovation.
SEC original ↗Tempus Ai, Inc. — 10-Q Quarterly report10-QJul 30, 2026
Risks & headwinds
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and its industry that involve substantial risks and uncertainties.
SEC original ↗Tempus Ai, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025
Legal Proceedings 58 Item 1A.
SEC original ↗Tempus Ai, Inc. — 10-Q Quarterly report10-QJul 30, 2026
11 Disaggregation of Revenue The Company provides disaggregation of revenue based on Diagnostics and Data and applications on the condensed consolidated statements of operations and comprehensive loss, as it believes these best depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
SEC original ↗Tempus Ai, Inc. — 10-Q Quarterly report10-QJul 30, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
33 documents- Q2 2026
- 10-QTEM
Jul 30, 2026
- 8-KTEM
Jul 30, 2026
- 8-KTEM
Jul 20, 2026
- 8-KTEM
Jul 20, 2026
- Q1 2026
- 8-KTEM
May 22, 2026
- 8-KTEM
May 13, 2026
- 10-QTEM
May 5, 2026
- 8-KTEM
May 5, 2026
- Q4 2025
- 10-KTEM
Feb 24, 2026
- 8-KTEM
Feb 24, 2026
- 8-KTEM
Jan 12, 2026
- EX-99TEM
Jan 12, 2026
- EX-99TEM
Jan 12, 2026
- Q3 2025
- 10-QTEM
Nov 4, 2025
- 8-KTEM
Nov 4, 2025
- Q2 2025
- 8-KTEM
Aug 27, 2025
- 10-QTEM
Aug 8, 2025
- 8-KTEM
Aug 8, 2025
- 8-KTEM
Jul 3, 2025
- Q1 2025
- 8-KTEM
May 23, 2025
- 10-QTEM
May 6, 2025
- 8-KTEM
May 6, 2025
- 8-KTEM
Apr 23, 2025
- Q4 2024
- 10-KTEM
Feb 24, 2025
- 8-KTEM
Feb 24, 2025
- 8-KTEM
Feb 3, 2025
- 8-KTEM
Jan 13, 2025
- EX-99TEM
Jan 13, 2025
- Q3 2024
- 8-KTEM
Nov 5, 2024
- 10-QTEM
Nov 4, 2024
- 8-KTEM
Nov 4, 2024
- Q2 2024
- 8-KTEM
Sep 6, 2024
- 8-KTEM
Aug 20, 2024
Earnings releases
11 documentsPresentations
0 documentsNo presentations for Tempus Ai, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Tempus Ai, Inc. are held in this edition of the library.
Mentioned by
6 companiesOther tracked companies whose held documents mention Tempus Ai, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“RD-LOOKING… …survey was completed during the first quarter of 2026. The survey used a LandTEM SQUID (Superconducting Quantum Interference Device) sensor, which generates higher quality data when compared to the historic EM surveys…”
“ net loss per share, basic $ (0.04… … 2,365,911 $ 2,274,838 Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands, except per share amounts) Six Months”
“al Cash Flow Information 27 17. Acquisitions and Divestitures 28 18. Seg ments 28 I TEM 2. MANAGEMENT ’ S DISCUSSION AND ANALYSIS OF FINANCIAL… …Stockholders $ 207 $ 168 $ 144 $ 916 Per Common Share Net Income (Loss) Attributable to Stockho”
“on-GAAP net loss per share, basic $ … … 2,135,091 $ 2,274,838 Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands, except per share amounts) Three Mont”
“tements that are not historical facts… …announcement on July 20, 2026 that Personalis and Tempus AI, Inc. have entered into an Agreement and Plan of Merger, Personalis will no longer provide financial guidance or conduct a quarterly earnings conferen”
Cass Information Systems Inc. (CASS)
“…providing for the sale of the TEM business. • Limited personnel expense growth to 1.4% despite AcuAudit acquisition and facility expense transaction volume increase. • Maintained exceptional”
See also the earnings calendar for every tracked company’s next earnings date.